RGNX Overview
Upcoming Projects (RGNX)
-
Analyzing Data from Phase 1/2/3 CAMPSIITE Trial of RGX-121 for MPS II (Hunter Syndrome) by REGENXBIO (RGNX)
Ticker: RGNX
Execute By: Nov 30, 2024 -
Evaluating Phase II ABBV-RGX-314 Study Results for Wet AMD from REGENXBIO (RGNX)
Ticker: RGNX
Execute By: Dec 31, 2024
Executed Projects (RGNX)
-
Discussing investigational therapies for the treatment of Hunter Syndrome, including DNL310 and RGX-121
Tickers: DNLI, RGNX
Executed On: Oct 04, 2024 at 04:00 PM EDT -
Evaluating Positive Phase I/II Results for RGX-202 in Duchenne Muscular Dystrophy from REGENXBIO Inc.
Ticker: RGNX
Executed On: Oct 03, 2024 at 03:30 PM EDT -
Discussing the phase I/II AFFINITY DUCHENNE clinical trial data on RGX-202 from REGENXBIO presented at WMS 2023
Ticker: RGNX
Executed On: Oct 19, 2023 at 04:15 PM EDT -
Exploring REGENXBIO Inc.'s RGX-202 for Duchenne Muscular Dystrophy (DMD)
Ticker: RGNX
Executed On: Sep 05, 2023 at 03:00 PM EDT -
Discussing Regenxbio’s RGX-314 in treating wet age-related macular degeneration
Ticker: RGNX
Executed On: Oct 24, 2022 at 08:00 PM EDT
Expired Projects (RGNX)
-
Charting a New Course in Hunter Syndrome Treatment: In-depth Analysis of REGENXBIO Inc.'s RGX-121 in the CAMPSIITE Trial for MPS II
Ticker: RGNX
Execute By: Mar 31, 2024 -
Discussing Regenxbio’s Phase I/II/III CAMPSIITE trial of RGX-121 recent data in Mucopolysaccharidosis Type II Hunter Syndrome
Ticker: RGNX
Execute By: Oct 31, 2022
Upcoming & Overdue Catalysts (RGNX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (RGNX)
-
REGENXBIO and Biogen Enter Exclusive License Agreement for the Development of Gene Therapy Treatments for Rare Genetic Vision Disorders
Tickers: RGNX, BIIB
Occurred on: May 16, 2016
Strategic Initiatives (RGNX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
